2026-02-24
SIRT3 and Mitochondrial Integrity: NAD-Dependent Deacetylase, Caloric Restriction Mimicry, and Activators
SIRT3 is the primary mitochondrial sirtuin — a NAD-dependent deacetylase that regulates ATP synthesis, ROS detoxification, and fatty acid oxidation. Its activity declines with age and NAD+ depletion. Activators include honokiol, urolithin A, and exercise, though human trial data is thin.
2026-02-17
SIRT3 Activators in Early Clinical Development: Mitochondrial Targets for Aging
SIRT3 is a mitochondrial deacetylase linked to energy efficiency and oxidative stress resistance. Novel small-molecule SIRT3 activators are in preclinical development; human efficacy data does not yet exist.
2026-02-11
Longevity Gene Activation: SIRT1, AMPK, mTOR, and NRF2 — Compound-by-Compound Evidence Map
Four gene networks — SIRT1 (longevity deacetylase), AMPK (energy sensor), mTOR (growth regulator), and NRF2 (antioxidant response) — are the primary longevity targets for supplement intervention. This article maps which compounds activate which genes, the quality of evidence, and where interactions become relevant.
2026-02-09
Calcium Alpha-Ketoglutarate and Epigenetic Aging: Biological Age Reduction Evidence
Calcium alpha-ketoglutarate (Ca-AKG) is an intermediate in the Krebs cycle and an alpha-ketoglutarate-dependent dioxygenase co-factor critical for epigenetic regulation. A clinical trial showed an 8-year reduction in biological age by DNA methylation clock. Evidence is early but striking.
2026-02-08
Epigenetic Reprogramming: Yamanaka Factors, Partial OSK Reprogramming, and the Clinical Horizon
Partial epigenetic reprogramming using OSK (Oct4, Sox2, Klf4) Yamanaka factors has reversed multiple aging hallmarks in animal models without inducing cancer. Human translation is in early clinical development. This article explains the biology, current trials, and realistic timeline.